InvestorWire NewsRoom

InvestorNewsBreak

InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Study Promising Candidate in Phase 2 GBM Trial
May 26, 2021

InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Study Promising Candidate in Phase 2 GBM Trial

CNS Pharmaceuticals (NASDAQ: CNSP) is on track to begin a potentially pivotal Phase 2 trial during the second quarter of 2021. This trial of CNSP’s lead drug candidate, Berubicin, in the treatment of glioblastoma multiforme (“GBM”) is currently planned to include up to 243 subjects, randomized 2:1 (162 Berubicin/81 Lomustine) with an interim analysis when 50% of the subjects reach six months in the study. “As the first anthracycline to cross the blood-brain barrier, Berubicin was specifically designed to attack a variety of primary brain cancers and cancers metastatic to the brain,” reads a recent article on the novel candidate. “Dr. Waldemar Priebe, professor of Medicinal Chemistry at The University of Texas MD Anderson Cancer Center, is the original developer of Berubicin. The Phase 1 trial was completed by Reata Pharmaceuticals (NASDAQ: RETA) and showed promising results, with 44% of the trial patients experiencing significant improvement in clinical benefit. One patient from this trial has survived cancer-free for the last 14 years, while two others saw a reduction in tumor size of up to 80%.”

To view the full article, visit https://ibn.fm/5Mutu

About CNS Pharmaceuticals Inc.

CNS Pharmaceuticals is developing novel treatments for primary and metastatic cancers of the brain and central nervous system. Its lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme, an aggressive and incurable form of brain cancer. For more information, visit the company’s website at www.CNSPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.investorwire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork.

Recent NewsBreaks

NewsBreaks Categories

Get Started with InvestorWire

To distribute a release in the next 24 hours. Contact our client services team.

(310) 299-1717

Distribute a press release. Submit your release to get started.

Submit Press Release

Set up a Live demonstration. Schedule a date and time that works for you.

Schedule a LIVE Demo

Press Distribution

Explore Press Distribution Solutions

All releases include an unlimited word count* with full wire-grade syndication, our press release enhancement service, and a follow-up InvestorNewsBreak article distributed to thousands of editorial syndication partners.

Discover Add-on Solutions

Increase the impact of your achievements by adding these exclusive solutions from InvestorWire, delivered in conjunction with the InvestorBrandNetwork (IBN).